Heather Woolery-Lloyd, MD

Ted Lain, MD, reviews available support groups, vitiligo education, and other resources for patients with the disease.

Tarasha, a patient with vitiligo, shares her story to help aid dermatologists and other physicians who treat people with the disease, and highlights the importance of transparent communication.

Heather Woolery-Lloyd, MD, and Tarasha comment on the impact of vitiligo on a patient’s quality of life and the importance of support for patients with vitiligo.

Heather Woolery-Lloyd, MD, and Ted Lain, MD, discuss the mechanism of action and efficacy of ruxolitinib cream in the treatment of vitiligo.

Ted Lain, MD, reviews the current treatment landscape for vitiligo, highlighting topical ruxolitinib as a major advancement.

Tarasha, a patient with vitiligo, shares the treatment regimen her dermatologist recommended and the importance of patient-physician communication.

Ted Lain, MD, shares his approach to evaluating patients with a vitiligo diagnosis and the search for concomitant disease.

A patient with vitiligo talks with Heather Woolery-Lloyd, MD, about her personal journey to diagnosis and struggles with the disease.

Expert dermatologists share final thoughts on treatment of vitiligo and topical ruxolitinib.

Experts in dermatology comment on the need to promote access to emerging treatments in vitiligo.

Heather Woolery-Lloyd, MD, and Nada Elbuluk, MD, share approaches to patient education and managing patient expectations when repigmenting the skin in vitiligo.

Expert dermatologists discuss the impact of vitiligo and vitiligo treatment on quality of life.

Nada Elbuluk, MD, and Ted Lain, MD, compare response to conventional treatment options vs emerging therapies, such as ruxolitinib, in the treatment of vitiligo.

Experts in dermatology share their impressions of ruxolitinib and approaches to vitiligo treatment in clinical practice.

Heather Woolery-Lloyd, MD, discusses the adverse event profile of topical ruxolitinib for treatment of vitiligo, highlighting the well-tolerated nature of the drug.

Expert dermatologists comment on the impact of UV light exposure on areas of the skin with vitiligo and their recommendations for sunscreen use.

Experts in dermatology review the mechanism of action and clinical trials of topical ruxolitinib for repigmenting the skin in vitiligo.

Brittany Craiglow, MD, discusses the lengthy nature of vitiligo treatment response and how to approach communicating with patients who want to see change quickly.

Ted Lain, MD, reviews the rates and patterns of repigmentation of the skin in vitiligo and how the timeline is different for each patient.

Expert dermatologists share approaches to treating patients with vitiligo, focusing on patient communication and the use of combination therapy.

Heather Woolery-Lloyd, MD, comments on the emotional impact of vitiligo on patients’ quality of life.

Ted Lain, MD, breaks down the use of the Vitiligo Area Scoring Index calculations to assess vitiligo severity.

Drs Brittany Craiglow and Nada Elbuluk review the precipitating factors that trigger vitiligo, as well as segmental vs nonsegmental vitiligo.

Dr. Woolery-Lloyd shares her advice for vitiligo providers and tips for helpful communication with patients.

Drs. Pandya, Rosmarin and King share their enthusiasm about emerging therapies and data that is available for ruxolitinib.

Vitiligo clinical experts discuss the role of maintenance therapy in preventing recurrence of vitiligo.

Drs. Woolery-Lloyd, King and Pandya discuss time to re-pigmentation of different areas in vitiligo.

Drs. Woolery-Lloyd, Rosmarin and Pandya discuss various treatment options for vitiligo and when and where they might use them.

Dr. Rosmarin and other panelists share their thoughts on how to treat different areas of the body and the role of tattoos.

Dr. Pandya shares his conversations with patients about re-pigmentation of segmental and non-segmental vitiligo and treatment options that exist.